MeiraGTx (MGTX) vs MannKind (MNKD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MeiraGTx (MGTX) has outperformed MannKind (MNKD) over the past year, gaining 27.4% versus a loss of 38.9%. Over five years, MGTX leads with a -24.2% price change compared with -32.2% for MNKD. MannKind is the larger company by market cap ($1.10 billion vs $1.01 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGTX | MNKD |
|---|---|---|
| Share price | $10.50 | $3.42 |
| Market cap | $1.01B | $1.10B |
| 1-day change | -2.96% | -0.87% |
| YTD return | +36.10% | -39.15% |
| 1-year return | +27.44% | -38.94% |
| 5-year return | -24.23% | -32.22% |
| P/E ratio (TTM) | 12.07 | — |
| Forward P/E | — | 26.82 |
| EPS (TTM) | $0.87 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.35 | $6.51 |
| 52-week low | $6.62 | $2.23 |
| Distance from 52-week high | -31.60% | -47.47% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +164.29% | +129.24% |
| Average volume | 797.37K | 4.48M |
| Shares outstanding | 96.04M | 321.54M |
| Employees | 393 | 591 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGTX has outperformed MNKD by 66.4 percentage points over the past year.
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
MGTX vs MNKD FAQ
Which is bigger, MeiraGTx or MannKind?
MannKind (MNKD) is larger, with a market capitalization of $1.10B compared with $1.01B for MeiraGTx (MGTX).
Which stock has performed better over the past year, MGTX or MNKD?
MGTX returned +27.44% over the past 12 months, compared with -38.94% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are MeiraGTx and MannKind in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for MeiraGTx and Biotechnology: Pharmaceutical Preparations for MannKind.